当前位置: X-MOL 学术HPB › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
PATCH-DP: a single-arm phase II trial of intra-operative application of HEMOPATCH™ to the pancreatic stump to prevent post-operative pancreatic fistula following distal pancreatectomy
HPB ( IF 2.7 ) Pub Date : 2021-06-09 , DOI: 10.1016/j.hpb.2021.05.007
Lev D Bubis 1 , Ramy Behman 1 , Rachel Roke 2 , Pablo E Serrano 3 , Jad A Khalil 4 , Natalie G Coburn 5 , Calvin H Law 5 , Kimberly Bertens 4 , Guillaume Martel 4 , Julie Hallet 5 , Michael Marcaccio 3 , Fady Balaa 4 , Douglas Quan 6 , Steven Gallinger 7 , Sulaiman Nanji 8 , Ken Leslie 6 , Ved Tandan 3 , Yigang Luo 9 , Gavin Beck 9 , Anton Skaro 6 , Deepak Dath 3 , Michael Moser 9 , Paul J Karanicolas 5 ,
Affiliation  

Background

Post-operative pancreatic fistula (POPF) is the most significant cause of morbidity following distal pancreatectomy. Hemopatch™ is a thin, bovine collagen-based hemostatic sealant. We hypothesized that application of Hemopatch™ to the pancreatic stump following distal pancreatectomy would decrease the incidence of clinically-significant POPF.

Methods

We conducted a prospective, single-arm, multicentre phase II study of application of Hemopatch™ to the pancreatic stump following distal pancreatectomy. The primary outcome was clinically-significant POPF within 90 days of surgery. A sample size of 52 patients was required to demonstrate a 50% relative reduction in Grade B/C POPF from a baseline incidence of 20%, with a type I error of 0.2 and power of 0.75. Secondary outcomes included incidence of POPF (all grades), 90-day mortality, 90-day morbidity, re-interventions, and length of stay.

Results

Adequate fixation Hemopatch™ to the pancreatic stump was successful in all cases. The rate of grade B/C POPF was 25% (95%CI: 14.0–39.0%). There was no significant difference in the incidence of grade B/C POPF compared to the historical baseline (p = 0.46). The 90-day incidence of Clavien–Dindo grade ≥3 complications was 26.9% (95%CI: 15.6–41.0%).

Conclusion

The use of Hemopatch™ was not associated with a decreased incidence of clinically-significant POPF compared to historical rates.

(NCT03410914).



中文翻译:

PATCH-DP:一项单臂 II 期试验,将 HEMOPATCH™ 术中应用于胰腺残端,以预防胰腺远端切除术后的术后胰瘘

背景

术后胰瘘 (POPF) 是远端胰腺切除术后发病的最重要原因。Hemopatch™ 是一种薄的、基于牛胶原蛋白的止血密封剂。我们假设在远端胰腺切除术后将 Hemopatch™ 应用于胰腺残端会降低临床显着 POPF 的发生率。

方法

我们进行了一项前瞻性、单臂、多中心 II 期研究,将 Hemopatch™ 应用于胰腺远端切除术后的胰腺残端。主要结果是手术后 90 天内有临床意义的 POPF。需要 52 名患者的样本量来证明 B/C 级 POPF 从 20% 的基线发生率相对降低 50%,I 型错误为 0.2,功效为 0.75。次要结局包括 POPF 的发生率(所有级别)、90 天死亡率、90 天发病率、再次干预和住院时间。

结果

在所有病例中,Hemopatch™ 充分固定到胰腺残端都是成功的。B/C 级 POPF 率为 25%(95%CI:14.0-39.0%)。与历史基线相比,B/C 级 POPF 的发生率没有显着差异(p = 0.46)。Clavien-Dindo ≥3 级并发症的 90 天发生率为 26.9%(95%CI:15.6-41.0%)。

结论

与历史发生率相比,使用 Hemopatch™ 与临床显着 POPF 发生率的降低无关。

(NCT03410914)。

更新日期:2021-06-09
down
wechat
bug